Lyka Labs Ltd
Incorporated in 1976, Lyka Labs Ltd is in the development, manufacture and marketing of quality finished dosages[1]
- Market Cap ₹ 415 Cr.
- Current Price ₹ 117
- High / Low ₹ 177 / 90.2
- Stock P/E 52.3
- Book Value ₹ 29.0
- Dividend Yield 0.00 %
- ROCE 9.93 %
- ROE 9.24 %
- Face Value ₹ 10.0
Pros
- Company has reduced debt.
Cons
- Stock is trading at 4.02 times its book value
- Company has a low return on equity of -0.48% over last 3 years.
- Company might be capitalizing the interest cost
- Debtor days have increased from 93.7 to 114 days.
- Working capital days have increased from 68.9 days to 102 days
* The pros and cons are machine generated. Pros / cons are based on a checklist to highlight important points. Please exercise caution and do your own analysis.
Peer comparison
Healthcare Healthcare Pharmaceuticals & Biotechnology Pharmaceuticals
Quarterly Results
Consolidated Figures in Rs. Crores / View Standalone
Profit & Loss
Consolidated Figures in Rs. Crores / View Standalone
Jun 2014 15m | Jun 2015 | Mar 2016 9m | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
119 | 166 | 130 | 110 | 60 | 71 | 61 | 86 | 194 | 93 | 111 | 138 | |
111 | 139 | 110 | 87 | 63 | 73 | 65 | 67 | 93 | 76 | 95 | 121 | |
Operating Profit | 8 | 28 | 20 | 23 | -4 | -2 | -4 | 20 | 101 | 17 | 16 | 18 |
OPM % | 7% | 17% | 16% | 21% | -6% | -3% | -6% | 23% | 52% | 18% | 14% | 13% |
25 | 4 | 8 | -2 | 4 | 1 | -30 | 0 | -4 | -4 | 1 | 2 | |
Interest | 27 | 24 | 15 | 19 | 10 | 7 | 20 | 26 | 20 | 12 | 5 | 2 |
Depreciation | 9 | 11 | 9 | 10 | 11 | 7 | 8 | 8 | 17 | 14 | 13 | 7 |
Profit before tax | -3 | -3 | 4 | -8 | -20 | -15 | -62 | -14 | 59 | -13 | -1 | 11 |
Tax % | 45% | 31% | -5% | -19% | -5% | -59% | 1% | -29% | 35% | -0% | 182% | 29% |
-5 | -5 | 4 | -7 | -19 | -6 | -63 | -10 | 38 | -13 | -3 | 8 | |
EPS in Rs | -3.05 | -2.29 | 1.67 | -2.51 | -6.14 | -1.97 | -21.10 | -4.03 | 13.59 | -4.30 | -0.75 | 2.22 |
Dividend Payout % | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% | 0% |
Compounded Sales Growth | |
---|---|
10 Years: | 2% |
5 Years: | 18% |
3 Years: | -11% |
TTM: | 25% |
Compounded Profit Growth | |
---|---|
10 Years: | 9% |
5 Years: | 18% |
3 Years: | -43% |
TTM: | 375% |
Stock Price CAGR | |
---|---|
10 Years: | 7% |
5 Years: | 47% |
3 Years: | -4% |
1 Year: | 9% |
Return on Equity | |
---|---|
10 Years: | % |
5 Years: | % |
3 Years: | 0% |
Last Year: | 9% |
Balance Sheet
Consolidated Figures in Rs. Crores / View Standalone
Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Equity Capital | 22 | 22 | 22 | 22 | 28 | 28 | 29 | 29 | 29 | 31 | 33 | 36 |
Reserves | 30 | 20 | 22 | 16 | 21 | 15 | -43 | -54 | -15 | 15 | 35 | 68 |
164 | 137 | 121 | 126 | 113 | 96 | 141 | 163 | 130 | 75 | 59 | 39 | |
113 | 100 | 77 | 88 | 67 | 76 | 73 | 52 | 42 | 31 | 30 | 33 | |
Total Liabilities | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 |
162 | 122 | 104 | 133 | 116 | 108 | 105 | 98 | 94 | 68 | 58 | 86 | |
CWIP | 22 | 27 | 30 | 24 | 28 | 31 | 28 | 26 | 18 | 16 | 23 | 0 |
Investments | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
145 | 130 | 107 | 94 | 85 | 77 | 68 | 66 | 74 | 67 | 76 | 90 | |
Total Assets | 329 | 279 | 242 | 252 | 229 | 216 | 200 | 190 | 186 | 152 | 157 | 176 |
Cash Flows
Consolidated Figures in Rs. Crores / View Standalone
Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
89 | 27 | 12 | 31 | 11 | 27 | 5 | 9 | 79 | 9 | 2 | 2 | |
-57 | 37 | 17 | -13 | -3 | -4 | -0 | -0 | -6 | 7 | -9 | -12 | |
-26 | -60 | -30 | -19 | -10 | -23 | 3 | -12 | -63 | -22 | 2 | 5 | |
Net Cash Flow | 6 | 4 | -1 | -0 | -3 | -1 | 9 | -3 | 10 | -5 | -6 | -5 |
Ratios
Consolidated Figures in Rs. Crores / View Standalone
Jun 2014 | Jun 2015 | Mar 2016 | Mar 2017 | Mar 2018 | Mar 2019 | Mar 2020 | Mar 2021 | Mar 2022 | Mar 2023 | Mar 2024 | Mar 2025 | |
---|---|---|---|---|---|---|---|---|---|---|---|---|
Debtor Days | 209 | 124 | 121 | 97 | 125 | 75 | 48 | 37 | 35 | 79 | 89 | 114 |
Inventory Days | 91 | 77 | 56 | 90 | 139 | 65 | 69 | 41 | 56 | 68 | 78 | 82 |
Days Payable | 363 | 220 | 218 | 266 | 301 | 216 | 192 | 141 | 96 | 91 | 98 | 98 |
Cash Conversion Cycle | -64 | -18 | -41 | -79 | -37 | -75 | -76 | -63 | -5 | 55 | 68 | 97 |
Working Capital Days | -106 | -88 | -75 | -191 | -456 | -181 | -156 | -71 | 6 | 34 | 71 | 102 |
ROCE % | 2% | 10% | 7% | 9% | -8% | -5% | -6% | 10% | 61% | 5% | 4% | 10% |
Documents
Announcements
- Announcement under Regulation 30 (LODR)-Newspaper Publication 28 May
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Annual Secretarial Compliance Report confirms regulatory compliance and 2.6 million shares issued on warrant conversion.
-
Compliances-Reg.24(A)-Annual Secretarial Compliance
27 May - Annual Secretarial Compliance Report confirms regulatory compliance; 26 lakh shares issued on warrant conversion; amalgamation scheme progress.
-
Approved The Appointment Of M/S. Kaushal Doshi & Associates, Practicing Company Secretaries (Firm Registration No. 106609 ) As The Secretarial Auditor Of The Company For A Period Of Five Consecutive Years, Subject To Approval Of The Shareholders At The Ensuing Annual General Meeting Of The Company
26 May - Approved FY25 audited results, director appointments, ESOS 2025, and AGM scheduled for 1 Aug 2025.
-
Appointment Of Cost Auditor
A. Approved The Appointment Of M/S. Rajaram M Walavalakar & Co., (FRN: 003584 ) Cost Accountants, As The Cost Auditors Of The Company For The Financial Year Ended 31St March, 2025 To Fill The Casual Vacancy Caused By The Resignation Of M/S. Sarvottam Rege & Associates.
B. Approved The Appointment Of M/S. Rajaram M Walavalakar & Co., (FRN: 003584 ) Cost Accountants, As The Cost Auditors Of The Company For The Financial Year Ended 31St March, 2026.
26 May - Approved FY25 audited results, director appointments, new auditors, ESOS 2025, and AGM on 1 Aug 2025.
Annual reports
-
Financial Year 2023
from bse
-
Financial Year 2022
from bse
-
Financial Year 2021
from bse
-
Financial Year 2020
from bse
-
Financial Year 2019
from bse
-
Financial Year 2018
from bse
-
Financial Year 2017
from bse
-
Financial Year 2016
from bse
-
Financial Year 2015
from bse
-
Financial Year 2014
from bse
-
Financial Year 2013
from bse
-
Financial Year 2012
from bse
-
Financial Year 2010
from bse
-
Financial Year 2010
from nse
-
Financial Year 2009
from bse
Business Overview:[1]
LLL is a WHO-GMP certified and ISO 9001- certified manufacturer of Pharmaceutical Formulations & Active Pharmaceutical Ingredients across various therapeutic segments, including Lyophilized injections, topical formulations of cream, ointment, foams, gels & lotions.